
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly has demonstrated strong revenue growth across multiple key segments, with cardiovascular revenues increasing by 16.1% year-over-year and neuromodulation revenues rising by 10% year-over-year in the fourth quarter. Notably, the company’s focus on innovative products such as Mounjaro and Verzenio has positioned it well within the rapidly evolving healthcare landscape, particularly in the cardiometabolic and oncology markets. Moreover, sustained growth projections for the electrophysiology market, estimated at around 15% annually, support Eli Lilly's potential for exceeding overall market performance in the coming years.
Bears say
Eli Lilly faced an 18% decline in its stock price following the release of disappointing Q4 results and a guidance for 2026 that fell short of consensus expectations, particularly within the electrophysiology (EP) segment. Factors contributing to a negative outlook include potential pricing and rebate pressures, slower-than-expected adoption of new products and M&A activities, and concerns regarding the efficacy of its key medications like tirzepatide in specific patient populations. Additionally, higher debt levels resulting from M&A could lead to negative financial leverage, creating further uncertainty around the company's growth trajectory and operational leverage ambitions.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares